Thomas Pabst

105PUBLICATIONS
287CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsGene and molecular therapyPredictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (105)

|Aug 27, 2026
Clinical Impact of a Common PDCD1 Germline Variant in DLBCL Patients Treated with CAR-T Cell Therapy.

|Jul 15, 2026
Clinical Impact of a Germline CD19 Variant on Treatment Outcome After CAR-T Cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma.

|Jul 15, 2026
Low-Frequency PPM1D Gene Mutations Affect Treatment Response to BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma.

|Jun 26, 2026
Influence of PPM1D Mutations on Response and Survival Outcomes Following Bispecific Antibody Therapy in Relapsed and Refractory Multiple Myeloma Patients.

|Jun 19, 2026
The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL).

|Jun 12, 2026
Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

Pageof 18

Frequent Collaborators

67 joint publications

Vera Ulrike Bacher

30 joint publications

Katja Seipel

17 joint publications

Michael Daskalakis

13 joint publications

Henning Nilius